- In January 2023, Ascendis Pharma announced positive results from a Phase III trial of its long-acting growth hormone therapy, showing significant improvements in growth rates in Turner Syndrome patients, paving the way for regulatory submissions.
- In June 2022, Novo Nordisk launched a new formulation of growth hormone therapy with enhanced delivery mechanisms, aiming to improve patient compliance and reduce treatment burden.
